Inhibition of the K+ Channel KCa3.1 Reduces TGF-β1-Induced Premature Senescence, Myofibroblast Phenotype Transition and Proliferation of Mesangial Cells
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of the K+ Channel KCa3.1 Reduces TGF-β1-Induced Premature Senescence, Myofibroblast Phenotype Transition and Proliferation of Mesangial Cells
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 1, Pages e87410
Publisher
Public Library of Science (PLoS)
Online
2014-01-29
DOI
10.1371/journal.pone.0087410
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Premature senescence and cellular phenotype transformation of mesangial cells induced by TGF-B1
- (2013) Rong-Guo Fu et al. RENAL FAILURE
- Role of Endothelial-Mesenchymal Transition (EndoMT) in the Pathogenesis of Fibrotic Disorders
- (2011) Sonsoles Piera-Velazquez et al. AMERICAN JOURNAL OF PATHOLOGY
- Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications
- (2011) José M López-Novoa et al. Journal of Translational Medicine
- STAT1 mediates cellular senescence induced by angiotensin II and H2O2 in human glomerular mesangial cells
- (2011) Sumin Jiao et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Review Article: Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis
- (2010) JINHUA LI et al. NEPHROLOGY
- Therapeutic potential of KCa3.1 blockers: recent advances and promising trends
- (2010) Heike Wulff et al. Expert Review of Clinical Pharmacology
- Endothelial-Myofibroblast Transition Contributes to the Early Development of Diabetic Renal Interstitial Fibrosis in Streptozotocin-Induced Diabetic Mice
- (2009) Jinhua Li et al. AMERICAN JOURNAL OF PATHOLOGY
- The K+channels KCa3.1 and Kv1.3 as novel targets for asthma therapy
- (2009) Peter Bradding et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effects of kynurenine metabolites on mesangial cell proliferation and gene expression
- (2009) Hiromitsu Yoshimura et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- TGF-beta signal transduction in chronic kidney disease
- (2009) H. et al. Frontiers in Bioscience-Landmark
- Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels
- (2009) I. Grgic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGF and K+ channel activity control normal and cystic fibrosis bronchial epithelia repair
- (2008) Nguyen Thu Ngan Trinh et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Local Delivery of the K Ca 3.1 Blocker, TRAM-34, Prevents Acute Angioplasty-Induced Coronary Smooth Muscle Phenotypic Modulation and Limits Stenosis
- (2008) D.L. Tharp et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?
- (2008) Chuan-Chu Chou et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Hydrophobic Interactions as Key Determinants to the KCa3.1 Channel Closed Configuration
- (2008) Line Garneau et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans
- (2008) Kazuyoshi Toyama et al. JOURNAL OF CLINICAL INVESTIGATION
- The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation
- (2008) F. Dorado et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis
- (2007) Surmeet Bedi et al. Transplantation Reviews
- Mitogenic modulation of Ca2+-activated K+ channels in proliferating A7r5 vascular smooth muscle cells
- (2006) Han Si et al. BRITISH JOURNAL OF PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now